Autocrine EGF and TGF‐α promote primary and acquired resistance to ALK/c‐Met kinase inhibitors in non‐small‐cell lung cancer
Abstract Drug resistance severely limits the clinical therapeutic value of molecularly targeted drugs. Growth factors gain a tremendous amount of focus due to the ability to promote drug resistance in non‐small‐cell lung cancer (NSCLC). However, whether tumor cells themselves can mediate drug resist...
Main Authors: | Yueqin Wang, Yu Zhang, Ruiying Chen, Xin Tian |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-02-01
|
Series: | Pharmacology Research & Perspectives |
Subjects: | |
Online Access: | https://doi.org/10.1002/prp2.1047 |
Similar Items
-
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
by: Mi Ran Yun, et al.
Published: (2019-12-01) -
Autocrine TGF-β in Cancer: Review of the Literature and Caveats in Experimental Analysis
by: Hendrik Ungefroren
Published: (2021-01-01) -
Research Progress of Acquired Resistance Mediated by MET Amplification
in Advanced Non-small Cell Lung Cancer
by: Sisi PAN, et al.
Published: (2022-08-01) -
Editorial: Primary and acquired resistance in lung cancer
by: Rossella Bruno, et al.
Published: (2023-11-01) -
Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1/STAT4 pathway
by: Bisheng Cheng, et al.
Published: (2024-03-01)